Immune system ↗The immune target is defined
A vaccine contains or generates antigen from a weakened or killed organism, a component, genetic instructions, or an inactivated toxin.
IMMUNE / 07
Practice the recognition.
Avoid the disease.
Vaccines present antigen in a controlled product-specific format, recruit innate presentation, expand matching lymphocyte clones, and leave memory that can reduce future infection, severe disease, or transmission according to the vaccine and pathogen.
Delivery changes cellular location
Live-attenuated, protein, conjugate, toxoid, viral-vector, and nucleic-acid platforms expose immune cells through different routes.
Innate context can be added
Some vaccines include adjuvants that improve antigen-presenting-cell activation and the magnitude or quality of the adaptive response.
Reactogenic symptoms may occur
Pain, swelling, fatigue, or fever can reflect local and systemic immune signaling but do not directly measure protection.
Antigen information reaches lymph
Activated antigen-presenting cells migrate to draining lymph nodes and display peptide with costimulatory context.
Helper T cells support antibody quality
Selected CD4 T cells provide signals required for strong germinal-center B-cell responses and class switching.
Some platforms recruit cytotoxic memory
Antigen access to MHC I and cross-presentation can generate CD8 T-cell responses, with magnitude differing by product.
Matching clones proliferate
B cells bind antigen and, with appropriate help, become germinal-center cells, memory cells, or antibody-secreting plasma cells.
Affinity improves through selection
Mutation and repeated selection enrich B-cell clones whose antibodies bind the vaccine antigen more effectively.
Protection uses multiple functions
Neutralization, opsonization, complement recruitment, and mucosal or systemic distribution vary by antibody class and infection.
Most activated cells decline
After the response peaks, short-lived effector cells fall while selected memory populations and long-lived plasma cells persist.
Re-exposure is recognized faster
Memory B and T cells lower the time needed for clonal expansion and effector production after a matching exposure.
Protection can change over time
Antibody concentration, memory quality, pathogen evolution, age, immune status, and exposure route influence durability.
Another dose can expand memory
Recommended additional doses can improve primary response rates, restore waning protection, broaden recognition, or update antigen match.
Protection is never an all-or-none switch
Vaccinated people can still be infected; benefit may be expressed as reduced likelihood of infection, severe disease, complications, or death.